Combined Analysis of Cyclooxygenase-2 Expression With p53 and Ki-67 in Nonsmall Cell Lung Cancer

Annals of Thoracic Surgery

Volumn 82, Issue 4, 2006, Pages 1198-1204

  Tsubochi, Hiroyoshi ^a   Sato, Nobuyuki ^b   Hiyama, Misae ^b   Kaimori, Mitsuomi ^b   Endo, Shunsuke ^a   Sohara, Yasunori ^a   Imai, Tadashi ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMICAL LABELING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX RATIO; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; RISK; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748744068     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2006.04.069     Document Type: Article

References (36)

1. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
2. Chan T.A., Morin P.J., Vogelstein B., and Kinzler K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95 (1998) 681-686
3. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
4. Stolina M., Sharma S., Lin Y., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164 (2000) 361-370
5. Miyata Y., Koga S., Kanda S., Nishikido M., Hayashi T., and Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9 (2003) 1741-1749
6. Sheng H., Shao J., Kirkland S.C., et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99 (1997) 2254-2259
7. Sawaoka H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274 (1998) G1061-G1067
8. Hida T., Kozaki K., Ito H., et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8 (2002) 2443-2447
9. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., and Tofilon P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91 (1999) 1501-1504
10. Trifan O.C., Durham W.F., Salazar V.S., et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62 (2002) 5778-5784
11. Altorki N.K., Keresztes R.S., Port J.L., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21 (2003) 2645-2650
12. Achiwa H., Yatabe Y., Hida T., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5 (1999) 1001-1005
13. Khuri F.R., Wu H., Lee J.J., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7 (2001) 861-867
14. Brabender J., Park J., Metzger R., et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 235 (2002) 440-443
15. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., and Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52 (1992) 4828-4831
16. Ebina M., Steinberg S.M., Mulshine J.L., and Linnoila R.I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54 (1994) 2496-2503
17. Yuan A., Yu C.J., Luh K.T., Kuo S.H., Lee Y.C., and Yang P.C. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 20 (2002) 900-910
18. Martin B., Paesmans M., Mascaux C., et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91 (2004) 2018-2025
19. KIP1 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 6 (2000) 4073-4081
20. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., and Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274 (1999) 10911-10915
21. Ferrandina G., Ranelletti F.O., Legge F., et al. Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 9 (2003) 4324-4331
22. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
23. Marrogi A.J., Travis W.D., Welsh J.A., et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 6 (2000) 4739-4744
24. Schreinemachers D.M., and Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5 (1994) 138-146
25. Moos P.J., Edes K., and Fitzpatrick F.A. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci USA 97 (2000) 9215-9220
26. Kastan M.B., and Zambetti G.P. Parc-ing p53 in the cytoplasm. Cell 112 (2003) 1-2
27. Moll U.M., LaQuaglia M., Benard J., and Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92 (1995) 4407-4411
28. Bosari S., Viale G., Roncalli M., et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 147 (1995) 790-798
29. Swamy M.V., Herzog C.R., and Rao C.V. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 63 (2003) 5239-5242
30. Gannon J.V., Greaves R., Iggo R., and Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9 (1990) 1595-1602
31. Niki T., Kohno T., Iba S., et al. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol 160 (2002) 1129-1141
32. Kaur B.S., Khamnehei N., Iravani M., Namburu S.S., Lin O., and Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 123 (2002) 60-67
33. Mao J.T., Fishbein M.C., Adams B., et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 12 (2006) 314-320
34. Denkert C., Kobel M., Pest S., et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160 (2002) 893-903
35. Ristimaki A., Sivula A., Lundin J., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62 (2002) 632-635
36. Xiao C.W., Liu J.M., Sirois J., and Goff A.K. Regulation of cyclooxygenase-2 and prostaglandin F synthase gene expression by steroid hormones and interferon-τ in bovine endometrial cells. Endocrinology 139 (1998) 2293-2299